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background
 
Intimal hyperplasia and resulting restenosis limit the efficacy of coronary stenting. We
studied a coronary stent coated with the antiproliferative agent paclitaxel as a means of
preventing restenosis.
 
methods
 
We conducted a multicenter, randomized, controlled, triple-blind study to evaluate the
ability of a paclitaxel-eluting stent to inhibit restenosis. At three centers, 177 patients
with discrete coronary lesions (<15 mm in length, 2.25 to 3.5 mm in diameter) under-
went implantation of paclitaxel-eluting stents (low dose, 1.3 µg per square millimeter,
or high dose, 3.1 µg per square millimeter) or control stents. Antiplatelet therapies in-
cluded aspirin with ticlopidine (120 patients), clopidogrel (18 patients), or cilostazol (37
patients). Clinical follow-up was performed at one month and four to six months, and
angiographic follow-up at four to six months.
 
results
 
Technical success was achieved in 99 percent of the patients (176 of 177). At follow-up,
the high-dose group, as compared with the control group, had significantly better
results for the degree of stenosis (mean [
 
±
 
SD], 14
 
±
 
21 percent vs. 39
 
±
 
27 percent;
P<0.001), late loss of luminal diameter (0.29
 
±
 
0.72 mm vs. 1.04
 
±
 
0.83 mm, P<0.001),
and restenosis of more than 50 percent (4 percent vs. 27 percent, P<0.001). Intravascu-
lar ultrasound analysis demonstrated a dose-dependent reduction in the volume of in-
timal hyperplasia (31, 18, and 13 mm
 
3
 
, in the high-dose, low-dose, and control groups,
respectively). There was a higher rate of major cardiac events in patients receiving cil-
ostazol than in those receiving ticlopidine or clopidogrel. Among patients receiving
ticlopidine or clopidogrel, event-free survival was 98 percent and 100 percent in the
high-dose and control groups, respectively, at one month, and 96 percent in both at
four to six months.
 
conclusions
 
Paclitaxel-eluting stents used with conventional antiplatelet therapy effectively inhibit
restenosis and neointimal hyperplasia, with a safety profile similar to that of standard
stents.
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ntimal hyperplasia after stent place-
 
ment and the resultant restenosis remain prob-
lematic despite numerous improvements in
stent technology and placement technique.
 
1-5
 
 In
the past decade, stents coated with antiproliferative
agents have been the focus of considerable research
because of their potential for eliminating resteno-
sis. Although many agents have failed preclinical
testing, paclitaxel and sirolimus (rapamycin) have
proceeded to clinical studies.
 
6-9
 
 In a previously pub-
lished study, sirolimus showed promise in reducing
restenosis.
 
7
 
 We present a randomized study of pac-
litaxel-coated stents.
Paclitaxel inhibits cell processes that are de-
pendent on microtubule turnover, including mito-
sis, cell proliferation, and cell migration, while the
cells remain viable and in a cytostatic state.
 
10-14
 
 In
vitro tests show cytostatic inhibition of smooth-
muscle cells with therapeutic concentrations of pac-
litaxel. For this reason, paclitaxel was considered
for intracoronary delivery to arrest the process re-
sponsible for neointimal hyperplasia after angio-
plasty and stenting.
 
14-17
 
Preclinical testing using a porcine coronary-
artery model showed inhibition of neointimal hy-
perplasia at one month over a range of doses, all
with acceptable safety. Although delayed endothe-
lialization was noted on histologic examination, re-
inforcing the need for antiplatelet therapy, results
did not suggest subacute thrombotic complications
while patients were receiving ticlopidine. In a sub-
sequent six-month study in which ticlopidine was
discontinued one month after stent implantation,
there were no late deaths from stent thrombosis.
Given this promising evidence of effectiveness and
acceptable safety profile, further study was consid-
ered to be warranted.
We designed a multicenter, prospective, random-
ized study to test the hypothesis that stents coated
with paclitaxel would inhibit neointimal hyper-
plasia in patients with coronary artery disease re-
quiring stenting of single new native lesions. Our
study, the Asian Paclitaxel-Eluting Stent Clinical
Trial (ASPECT), compared the safety and effective-
ness of paclitaxel-eluting stents with the safety and
effectiveness of uncoated stents of the same type.
 
selection of patients
 
Symptomatic patients were included if they were at
least 18 years old and volunteered for follow-up.
Criteria for exclusion included an ejection fraction
of less than 35 percent; coagulopathy; intractable
hypersensitivities; the performance of other stud-
ies within the previous 30 days; pregnancy; a life ex-
pectancy of less than 1 year; myocardial infarction
within the previous 72 hours; other revasculariza-
tion procedures within the previous 1 month; the
presence of coronary thrombus; severe calcification;
total occlusion; another stenosis of more than 50
percent in the target vessel; a lesion length greater
than 15 mm; multiple stents; proximal tortuosity;
angulation of more than 45 percent; unprotected
left-main coronary lesions; and poor distal runoff.
The protocol was approved by the appropriate ethics
committees. Participants gave written informed con-
sent, and the study was conducted between January
2000 and March 2001 in accordance with the Dec-
laration of Helsinki.
 
study design
 
The three-center randomized study compared stents
coated with one of two doses of paclitaxel with an
uncoated control stent of the same design. The study
population was stratified according to stent diam-
eter and was randomized in blocks (in a ratio of
1:1:1). Stents (Cook) of each diameter were ordered
in a randomized sequence. After angiography to
determine vessel diameter, stents of the appropriate
diameter were selected in order of sequence. The
patients, investigators, and core-analysis labora-
tories were all unaware of the random group as-
signments.
 
angioplasty and stenting procedure
 
Standard angioplasty and stent placement were
performed with a radial or femoral approach and
an over-the-wire technique. Lesions were predilat-
ed with a standard balloon equal to or smaller than
the diameter of the reference vessel. The stent, pre-
mounted on a semicompliant balloon, was chosen
to achieve a stent-to-artery ratio of approximately
1.1:1.0. The stent was delivered by low-pressure in-
flation and dilated if necessary to achieve minimal
residual stenosis (<10 percent). In the event of a dis-
tal or proximal dissection, a second uncoated stent
of either the study type or another type was placed.
The stent used in the study was a 15-mm-long
Supra-G stent (Cook) in diameters of 2.5, 3.0, and
3.5 mm. The polished stainless-steel, laser-cut can-
nula design had a large surface area (42 to 47 mm
 
2
 
,
depending on the diameter). A proprietary proc-
ess was used to bond paclitaxel, at a dose density
i
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of 3.1 µg per square millimeter or 1.3 µg per square
millimeter, to the abluminal surface of the stents
without the use of a polymer. The total amount of
paclitaxel per stent was 130 to 146 µg in the group
that received stents with the dose of 3.1 µg per
square millimeter and 54 to 60 µg in the group that
received stents with the dose of 1.3 µg per square
millimeter, depending on the diameter of the stent.
The protocol recommended treatment with sol-
uble aspirin and clopidogrel or ticlopidine before
the procedure. Heparin was administered during the
procedure according to standard practice. After
the procedure, in addition to aspirin, ticlopidine or
clopidogrel was recommended for one month at
two centers and for six months at the third center.
Cilostazol
 
18-20
 
 was administered in lieu of ticlopi-
dine or clopidogrel in 37 patients, as was standard
practice for patients with stents at two centers.
 
study end points
 
Clinical follow-up was performed at one month
and again at four to six months; angiographic fol-
low-up was performed at four to six months. The
primary end point was the percentage stenosis at
angiographic follow-up, as determined by inde-
pendent quantitative angiographic analysis. Sec-
ondary angiographic end points included late loss,
the rate of restenosis (defined as stenosis of more
than 50 percent of the luminal diameter), and the
in-stent minimal luminal diameter. Secondary clin-
ical end points included the incidence of death,
acute and subacute thrombosis, the need for cor-
onary bypass surgery or intervention to treat clin-
ical ischemia due to restenosis of the target lesion,
and myocardial infarction (Q-wave or non–Q-wave)
due to restenosis of the target lesion. Q-wave my-
ocardial infarction was defined by the postproce-
dural presence of new Q waves greater than 0.04
second in two contiguous leads. Non–Q-wave myo-
cardial infarction was defined as investigator-iden-
tified, clinically significant myocardial infarction
involving peak creatine kinase values greater than
twice the upper limit of normal and a creatine kinase
MB fraction greater than twice the upper limit of
normal.
Clinical events were adjudicated by an independ-
ent clinical-events committee (Harvard Clinical Re-
search Institute, Boston). Safety data were reviewed
by an independent data safety monitoring board
(Willis Tacker, M.D., Ph.D., Seattle, Chairman). Data
were collected with standardized case-report forms
that were completed by the research coordinator at
each site. Representatives from the data-coordinat-
ing center monitored the sites.
 
angiographic analysis
 
Procedural and follow-up angiograms were submit-
ted to an independent angiographic core labora-
tory (Methodist Hospital, Houston). Quantitative
angiographic analysis was performed (CAAS II, Pie
Medical) for standard qualitative and quantitative
characteristics such as luminal dimensions, includ-
ing proximal and distal references, and the mini-
mal luminal diameter before and after the proce-
dure and at follow-up. Angiograms were evaluated
qualitatively for morphologic features of the lesion,
flow grade, dissection grade, and branches larger
than 2 mm.
 
intravascular-ultrasound substudy
 
Eighty-one patients at one center underwent an in-
travascular-ultrasound substudy designed to pro-
vide more detailed information about the mecha-
nism of inhibition of restenosis. Automatic pullback
images were obtained after stent placement and at
four to six months of follow-up. Imaging extended
up to 5 mm distally and 5 mm proximally in most
patients. The postprocedural and follow-up im-
ages were submitted to an independent, blinded
core laboratory (Cardiovascular Research Institute,
Washington, D.C.) for analysis. Luminal, stent, ves-
sel, and neointimal volumes were calculated from
automated pullback images with use of Simpson’s
rule with 1-mm intervals.
 
statistical analysis
 
The study was designed by the academic investiga-
tors and commercial sponsor and had sufficient
power to detect a 15 percent difference in the angio-
graphically determined percentage of stenosis at
six months, for an alpha level of 0.05 and a beta of
0.20; it was calculated that a minimum of 50 pa-
tients was required per treatment group, assuming
a 90 percent follow-up.
Continuous variables are reported as means 
 
±
 
SD.
Effects across all three groups were analyzed by
analysis of variance, and pairwise comparisons
were performed with an unpaired t-test. Dichoto-
mous variables are reported as percentages with 95
percent confidence intervals; comparisons were per-
formed with a Pearson’s chi-square or Fisher’s ex-
act test. Analysis was performed on an intention-to-
treat basis including all patients for whom data
were available from the follow-up analysis. All data
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were available to the investigators, and the data anal-
ysis was performed independently of the sponsor.
 
demographic and clinical characteristics
 
Between January 2000 and March 2001, 177 patients
were enrolled: 60 in the high-dose group, 58 in the
low-dose group, and 59 in the control group. Stent
implantation was successful in 176 patients (99.4
percent); 1 patient did not receive a stent because of
tortuosity. Analysis of demographic and base-line
characteristics showed no significant differences
among groups (Table 1). The patients’ characteris-
tics were typical of those of patients with noncom-
plex lesions. Multivessel disease was present in 40
percent of the patients. The lesions treated are de-
scribed qualitatively and quantitatively as assessed
by the independent core laboratory in Table 2; no
significant differences existed among the groups.
At discharge, all but one patient received aspi-
rin, and no patient received warfarin. In addition to
aspirin, 120 received ticlopidine after the proce-
dure and at discharge (26 for one month and 94 for
six months); of these, 1 also received postprocedur-
al abciximab, and 3 also received postprocedural
standard heparin. Eighteen received clopidogrel
for one month, without postprocedural abciximab
or heparin. Thirty-seven received cilostazol (29 for
one month and 8 for six months); 1 also had abcix-
imab after the procedure, and 3 had standard hep-
arin after the procedure. One patient received aspi-
rin and ticlopidine after the procedure but did not
take aspirin or ticlopidine after discharge, because
of clinically significant urethral bleeding.
 
angiographic outcomes
 
Angiographic measures are shown in Table 3; an-
giographic follow-up was obtained for 155 patients
(88 percent), at a mean of 174
 
±
 
44 days (range, 85 to
412, including early symptomatic interventions).
The results demonstrated a dose-dependent reduc-
tion in the primary end point, the percentage of ste-
nosis (39
 
±
 
27 percent in the control group, vs. 23
 
±
 
25
percent in the low-dose group and 14
 
±
 
21 percent
in the high-dose group; P<0.001).
Late loss of luminal diameter involved a dose-
dependent reduction as well (1.04±0.83 mm in the
controls, 0.57
 
±
 
0.71 mm in the low-dose group, and
0.29
 
±
 
0.72 mm in the high-dose group; P<0.001).
In the calculation of the late-loss index as the slope
of the regression line on a graph of late loss versus
acute gain, only the control group yielded a slope.
In the paclitaxel groups, the correlation coefficient
was near zero, indicating no relation between late
loss and immediate gain (the luminal diameter im-
mediately after the procedure minus the luminal
diameter before the procedure). In lieu of a late-loss
index we calculated the late loss divided by the im-
mediate gain for each patient; this ratio was reduced
from 0.46
 
±
 
0.37 in the control group to 0.26
 
±
 
0.34
and 0.13
 
±
 
0.33 in the low-dose and high-dose
groups, respectively (P<0.001).
The rate of restenosis, defined as stenosis of
more than 50 percent, was 27 percent in the con-
trol group, 12 percent in the low-dose group, and
4 percent in the high-dose group (P<0.001). These
reductions were associated with a dose-dependent
improvement in the minimal luminal diameter
(1.79
 
±
 
0.86 mm in the controls, vs. 2.28
 
±
 
0.83 mm
in the low-dose group and 2.53
 
±
 
0.72 mm in the
high-dose group; P<0.001).
results
 
* There were no significant differences among the treatment groups. Plus–minus 
 
values are means ±SD.
 
Table 1. Base-Line Demographic Characteristics of the Patients.*
Variable Dose of Paclitaxel
Total
(N=177)
 
3.1 
µg/mm
 
2
 
(N=60)
1.3 
µg/mm
 
2
 
(N=58)
0 
µg/mm
 
2
 
(N=59)
Age — yr 58±9 60±9 58±11 60±10
Male sex — no. (%) 48 (80) 42 (72) 45 (76) 135 (76)
Diabetes mellitus — no. (%) 11 (18) 14 (24) 10 (17) 35 (20)
Hypercholesterolemia — no. (%) 8 (13) 4 (7) 11 (19) 23 (13)
Hypertension — no. (%) 25 (42) 31 (53) 28 (47) 84 (47)
Smoking — no. (%)
Never
Past
Current
Unknown
21 (35)
8 (13)
28 (47)
3 (5)
23 (40)
11 (19)
23 (40)
1 (2)
24 (41)
8 (14)
27 (46)
0
68 (39)
27 (15)
78 (44)
0
Obesity — no. (%) 5 (8) 3 (5) 1 (2) 9 (5)
Prior myocardial infarction 
— no. (%)
14 (23) 13 (22) 17 (29) 44 (25)
Prior coronary-artery bypass graft 
— no. (%)
2 (3) 1 (2) 0 3 (2)
No. of diseased vessels — no. (%)
1
2
3
4
32 (53)
20 (33)
8 (13)
0
36 (62)
17 (29)
4 (7)
1 (2)
39 (66)
15 (25)
5 (8)
0 
107 (60)
52 (29)
17 (10)
1 (1)
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Cumulative distribution curves demonstrated a
dose-dependent reduction in the degree of steno-
sis, as shown in Figure 1 for the high-dose group as
compared with the control group. Distributions
were similar at base line and immediately after stent
placement. At follow-up, the distribution in the
high-dose group was similar to the distribution
immediately after stenting.
 
intravascular ultrasound
 
Intravascular-ultrasound analysis of 81 patients
showed a dose-dependent reduction in the volume
of neointimal hyperplasia at follow-up (31
 
±
 
22 mm
 
3
 
in the controls, 18
 
±
 
15 mm
 
3
 
 in the low-dose group,
and 13
 
±
 
14 mm
 
3 
 
in the high-dose group; P<0.001).
There were no significant differences in any vol-
umes after the procedure, and no significant differ-
ences in stent or vessel volume at follow-up.
 
safety at one and six months
 
Clinical follow-up was obtained for all patients who
received stents at one month and four to six months
(135
 
±
 
30 days; range, 57 to 201, including early
symptomatic interventions). Major adverse cardiac
events are shown in Table 4. Events were classified
according to antiplatelet therapy because an adverse
effect of cilostazol was observed. Of 138 patients
receiving ticlopidine or clopidogrel, the only event
reported at one month was a non–Q-wave myocar-
dial infarction due to closure of a side branch evi-
dent during stent placement, which was dilated. In
37 patients receiving cilostazol, there were 1 death
and 4 subacute thromboses treated with repeated
angioplasty within one month. Potential contribut-
ing factors included a stent shorter than the lesion,
leaving a dissection uncovered, in one case, and a
thrombus that was untreated after stenting in an-
other. In each of the three groups, two patients
underwent target-lesion revascularization for re-
stenosis within six months. There were no addition-
al events after one month, even for the 73 patients
whose ticlopidine, clopidogrel, or cilostazol ther-
apy was discontinued after only one month.
This study clearly shows that a paclitaxel-coated
coronary stent can significantly reduce restenosis
in the six months after intervention, thereby ad-
dressing a major problem that has plagued angio-
plasty since its inception and has not been adequate-
ly addressed by the introduction of stents. The dose
of 3.1 µg per square millimeter was the more effec-
tive of the two doses tested and had safety similar
to that of other doses within the follow-up period
studied, when used with conventional antiplatelet
therapy.
The intravascular-ultrasound substudy showed
that the reduction in the percentage of stenosis and
in late loss and the increase in the minimal luminal
diameter were directly due to a reduction in the pro-
liferation of neointimal tissue. They were not asso-
ciated with a high degree of positive remodeling.
discussion
 
* There were no significant differences among the treatment groups.
 
Table 2. Characteristics of the Lesions in Patients Who Received Stents.*
Variable Dose of Paclitaxel
Total
(N=176)
 
3.1 
µg/mm
 
2
 
(N=59)
1.3 
µg/mm
 
2
 
(N=58)
0 
µg/mm
 
2
 
(N=59)
 
no. (%)
 
Vessel stented
Left anterior descending
coronary artery
Right coronary artery
Left circumflex coronary 
artery
Ramus
31 (53)
10 (17)
17 (29)
1 (2)
29 (50)
18 (31)
10 (17)
1 (2)
30 (51)
17 (29)
12 (20)
0
90 (51)
45 (26)
39 (22)
2 (1)
Lesion classification
A
B1
B2
C
29 (49)
26 (44)
4 (7)
0
35 (60)
21 (36)
1 (2)
1 (2)
30 (51)
24 (41)
5 (8)
0
94 (53)
71 (40)
10 (6)
1 (1)
Proximal tortuosity
None
Mild
Moderate
Severe
37 (63)
21 (36)
1 (2)
0
36 (62)
19 (33)
3 (5)
0
32 (54)
26 (44)
1 (2)
0
105 (60)
66 (38)
5 (3)
0
Calcification
None
Mild
Moderate
Severe
52 (88)
7 (12)
0
0
49 (84)
9 (16)
0
0
47 (80)
9 (15)
3 (5)
0
148 (84)
25 (14)
3 (2)
0
Shape
Concentric
Eccentric
25 (42)
34 (58)
29 (50)
29 (50)
25 (42)
34 (58)
79 (45)
97 (55)
Angulation >45 degrees 1 (2) 1 (2) 0 2 (1)
Other stenosis 2 (3) 4 (7) 4 (7) 10 (6)
Ostial 1 (2) 1 (2) 1 (2) 3 (2)
Branch 4 (7) 6 (10) 7 (12) 17 (10)
Thrombus 0 1 (2) 0 1 (1)
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The concept that a bigger stent is better has been
predicated on the late-loss index, indicating that
approximately half the immediate gain is lost with-
in six months.
 
21
 
 Although other therapies such as
brachytherapy
 
22,23
 
 have reduced the late-loss index,
in this study we found a near-zero correlation coef-
ficient for paclitaxel-eluting stents. This suggests
the bigger-is-better concept may not apply to drug-
eluting stents.
The major adverse cardiac events within one
month suggest that the paclitaxel-eluting stent is
safe at both low and high dose densities if used
with conventional thianopyridine antiplatelet ther-
apy. The single event was due to closure of an in-
volved side branch evident at the time of the pro-
cedure and therefore appeared to be unrelated to
the coating. The incidence of subacute thrombotic
events in patients who received cilostazol instead
of ticlopidine or clopidogrel suggests that antiplate-
let agents may be more important for drug-eluting
stents than for uncoated stents and that cilostazol
is an inadequate substitute for thianopyridines with
paclitaxel-eluting stents.
The absence of additional deaths, myocardial
infarctions, or emergency bypass surgeries between
one and six months after the procedure suggests
that the paclitaxel-eluting stent is reasonably safe
during this period at the dose densities studied. The
number of additional target-lesion revasculariza-
tions for restenosis was similar among treatment
groups, despite the significant difference in all an-
giographic measures of restenosis. This apparent
discrepancy was due to the pattern of clinical prac-
tice in the participating centers, in which angio-
graphic restenosis is not treated with intervention
 
* The numbers of patients for whom there were measurements before and after the procedure were as follows: 58 in the 
high-dose group, 57 in the low-dose group, and 57 in the control group. For follow-up measurements, the numbers were 
 
50 in the high-dose group, 50 in the low-dose group, and 55 in the control group. Plus–minus values are means ±SD.
 
Table 3. Angiographic Measures, According to the Dose of Paclitaxel.*
Variable Dose of Paclitaxel
P Value
(High Dose vs. Control)
 
3.1 µg/mm
 
2
 
1.3 µg/mm
 
2
 
0 µg/mm
 
2
 
Lesion length (mm) 10.9±3.6 11.2±3.2 10.5±3.1 0.52
Diameter of reference vessel (mm) 2.94±0.39 2.93±0.38 2.88±0.36 0.69
Stenosis (% of luminal diameter)
Before procedure
After procedure
At follow-up
79.4±9.0
1.87±5.38
14±21
80.1±8.0
3.27±5.03
23±25
80.9±9.9
3.77±8.42
39±27
0.14
0.67
<0.001
Minimal luminal diameter (mm)
Before procedure
After procedure
At follow-up
0.64±0.29
2.85±0.34
2.53±0.72
0.57±0.25
2.84±0.39
2.28±0.83
0.54±0.33
2.82±0.42
1.79±0.86
0.19
0.92
<0.001
Late loss (mm) 0.29±0.72 0.57±0.71 1.04±0.83 <0.001
Average loss or gain (mm) 0.13±0.33 0.26±0.34 0.46±0.37 <0.001
Restenosis (% of patients) 4 12 27 <0.001
 
Figure 1. Cumulative Distribution of the Percentage of Stenosis in the High-
Dose and Control Groups.
 
The distributions were similar at base line and immediately after stent place-
ment. At six months, the distribution in the high-dose group remained similar 
to the distribution immediately after stenting.
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unless the patient’s symptoms are untreatable with
medication. Clinical experience at these and other
centers suggests that late regression of the stenosis
may occur without intervention.
 
24-27
 
 In addition,
the predominantly simple lesions treated in the
study may also contribute to the lack of difference
in the rates of revascularization. However, conclu-
sions regarding clinical effect are tentative in this
study, whose size was based on an angiographic end
point. Nevertheless, given the practice pattern, du-
ration of follow-up, simplicity of lesions, and sam-
ple size, the angiographic benefit was not reflected
in a beneficial difference in revascularization rates.
The absence of late events also speaks to the is-
 
* MI denotes myocardial infarction.
† One patient in the control group, who was event-free, did not receive antiplatelet therapy after discharge and is not included in the table.
‡ The non–Q-wave myocardial infarction occurred in the first 30 days. The infarction was related to side-branch closure during stenting.
§ Subacute thrombosis was treated with repeated angioplasty; P<0.001 for the effect of cilostazol as compared with that of ticlopidine or clo-
pidogrel.
¶ P<0.001 for the effect of cilostazol as compared with that of clopidogrel. Event-free data were calculated on a per-patient basis (multiple 
events occurred in some patients).
¿ All non–Q-wave myocardial infarctions occurred in the first 30 days.
**P=0.007 for the effect of cilostazol as compared with that of clopidogrel. Event-free data were calculated on a per-patient basis (multiple 
 
events occurred in some patients).
 
Table 4. Safety Data at One and Six Months According to Antiplatelet Therapy and Dose of Paclitaxel.*
Variable
Aspirin with Ticlopidine 
or Clopidogrel Aspirin with Cilostazol All
 
3.1 µg 
of pacli-
taxel/
mm
 
2
 
1.3
 
 
 
µg 
of pacli-
taxel/
mm
 
2
 
0 µg 
of pacli-
taxel/
mm
 
2
 
Total
3.1
 
 
 
µg 
of pacli-
taxel/
mm
 
2
 
1.3
 
 
 
µg 
of pacli-
taxel/
mm
 
2
 
0
 
 
 
µg 
of pacli-
taxel/
mm
 
2
 
Total
3.1
 
 
 
µg 
of pacli-
taxel/
mm
 
2
 
1.3
 
 
 
µg 
of pacli-
taxel/
mm
 
2
 
0 µg 
of pacli-
taxel/
mm
 
2
 
Total†
No. of patients 47 43 48 138 12 15 10 37 59 58 58 175
 
One-month results
 
Death (no.) 0 0 0 0 0 1 0 1 0 1 0 1
Coronary bypass
surgery (no.)
0 0 0 0 0 0 0 0 0 0 0 0
Q-wave MI (no.) 0 0 0 0 0 0 0 0 0 0 0 0
Non–Q-wave MI 
(no.)
1‡ 0 0 1‡ 1 1 1 3 2 1 1 4
Subacute thrombosis
(no.)§
0 0 0 0 3 1 0 4 3 1 0 4
Event-free (%)¶ 98 100 100 99 75 87 90 84 93 97 98 96
 
Six-month results
 
Death (no.) 0 0 0 0 0 1 0 1 0 1 0 1
Coronary bypass 
surgery (no.)
0 0 0 0 0 0 0 0 0 0 0 0
Q-wave MI (no.) 0 0 0 0 0 0 0 0 0 0 0 0
Non–Q-wave MI 
(no.) (all 30 days)¿
1‡ 0 0 1‡ 1 1 1 3 2 1 1 4
Subacute thrombosis
(no.)§
0 0 0 0 3 1 0 4 3 1 0 4
Target-lesion 
revascularization
for restenosis 
at 1–6 mo (no.)
1 2 2 5 1 0 0 1 2 2 2 6
Event-free (%)** 96 95 96 96 67 87 90 81 90 93 95 93
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sue of extended antiplatelet therapy. Although pre-
clinical studies suggested a small delay in reendo-
thelialization,
 
28
 
 in this clinical study, discontinuation
of ticlopidine at one month was not associated with
late thrombosis-related events between one and six
months. Although the sample size was not suffi-
cient to rule out the need for the extended therapy,
there were no deaths, myocardial infarctions, or
emergency surgeries between one and six months
in the subgroup of 73 patients who received only
aspirin after the first month. However, early events
among the patients treated with cilostazol suggest
that specific, effective antiplatelet therapy is required
with antiproliferative-eluting stents.
The results of this study of paclitaxel are similar
to those of the Randomized Study with the Siroli-
mus-Coated Bx Velocity Balloon-Expandable Stent
in the Treatment of Patients with de Novo Native
Coronary Artery Lesions (RAVEL) of sirolimus.
 
7
 
Both demonstrate the potential of antiproliferative
agents to reduce restenosis by inhibiting neointi-
mal hyperplasia.
The study did not have sufficient power to iden-
tify infrequent risks, to define fully the need for ex-
tended antiplatelet therapy, to explain the observed
effect of cilostazol fully, or to assess effectiveness
in more complex lesions. The six-month follow-up
period leaves unanswered the question of the du-
ration of the benefits seen at six months and the
possible long-term adverse effects of drug-eluting
stents, whether the drug eluted is paclitaxel or an-
other agent. Larger studies are needed to evaluate
more adequately the clinical effect of the use of coat-
ed stents for the elimination of restenosis.
From these data, we conclude that paclitaxel-
eluting coronary stents significantly improved the
angiographic outcome six months after percutane-
ous transluminal coronary intervention by reducing
neointimal hyperplasia after stent placement, result-
ing in increased vessel diameter, reduced stenosis,
and reduced binary restenosis at follow-up. Paclitax-
el had a safety profile similar to that of the control
stent when used with conventional antiplatelet ther-
apy. The use of cilostazol appeared to be associat-
ed with subacute closure in a few patients. Of the
dose densities tested, 3.1 µg per square millimeter
of abluminal stent surface was the more effective.
 
Supported by a grant from Cook.
Dr. Weissman reports having received a research grant from
Medstar Research Institute, and Dr. Mintz reports having received
lecture fees from Boston Scientific.
We are indebted to Dr. Jae-Joong Kim, Dr. Nam Sik Chung, Dr.
Seong Yun Cho, and Dr. Yan Wang for their participation in this clin-
ical trial; to Dong Soon Shin, Kyung Hea Park, and Young-Rok Han
for research coordination; to Anthony O. Ragheb, Ph.D., for preclin-
ical studies; and to Neal E. Fearnot, Ph.D., and William D. Voorhees,
Ph.D., for trial direction and data analysis.
 
references
 
1.
 
Lowe HC, Oesterle SN, Khachigian LM.
Coronary in-stent restenosis: current status
and future strategies. J Am Coll Cardiol 2002;
39:183-93.
 
2.
 
Hoffmann R, Mintz GS, Dussaillant GR,
et al. Patterns and mechanisms of in-stent
restenosis: a serial intravascular ultrasound
study. Circulation 1996;94:1247-54.
 
3.
 
Hanke H, Kamenz J, Hassenstein S, et al.
Prolonged proliferative response of smooth
muscle cells after experimental intravascu-
lar stenting. Eur Heart J 1995;16:785-93.
 
4.
 
Moreno PR, Palacios IF, Leon MN,
Rhodes J, Fuster V, Fallon JT. Histopatho-
logic comparison of human coronary in-stent
and post-balloon angioplasty restenotic tis-
sue. Am J Cardiol 1999;84:462-6.
 
5.
 
Weissman NJ, Wilensky RL, Tanguay JF,
et al. Extent and distribution of in-stent inti-
mal hyperplasia and edge effect in a non-radi-
ation stent population. Am J Cardiol 2001;
88:248-52.
 
6.
 
de Feyter PJ, Vos J, Rensing BJ. Anti-
restenosis trials. Curr Interv Cardiol Rep
2000;2:326-31.
 
7.
 
Morice M-C, Serruys PW, Sousa JE, et al.
A randomized comparison of a sirolimus-
eluting stent with a standard stent for coro-
nary revascularization. N Engl J Med 2002;
346:1773-80.
 
8.
 
Sousa JE, Costa MA, Abizaid AC, et al.
Sustained suppression of neointimal prolif-
eration by sirolimus-eluting stents: one-year
angiographic and intravascular ultrasound
follow-up. Circulation 2001;104:2007-11.
 
9.
 
Rensing BJ, Vos J, Smits PC, et al. Coro-
nary restenosis elimination with a sirolimus
eluting stent: first European human experi-
ence with 6-month angiographic and intra-
vascular ultrasound follow-up. Eur Heart J
2001;22:2125-30.
 
10.
 
Shiff PB, Fant J, Horwitz SB. Promotion
of microtubule assembly in vitro by Taxol.
Nature 1979;277:665-7.
 
11.
 
Rowinsky EK, Cazenave LA, Donehower
RC. Taxol: a novel investigational antimi-
crotubule agent. J Natl Cancer Inst 1990;
82:1247-59.
 
12.
 
Rowinski EK, Eisenhauer EA, Chaudhry
V, Arbuck SG, Donehower RC. Clinical tox-
icities encountered with paclitaxel (Taxol).
Semin Oncol 1993;20:Suppl 3:1-15.
 
13.
 
Rowinsky EK, Donehower RC. Pacli-
taxel (Taxol). N Engl J Med 1995;332:1004-
14. [Erratum, N Engl J Med 1995;333:75.]
 
14. Axel DI, Kunert W, Göggelmann C, et al.
Paclitaxel inhibits arterial smooth muscle
cell proliferation and migration in vitro and
in vivo using local drug delivery. Circulation
1997;96:636-45.
15. Heldman AW, Cheng L, Jenkins GM, et
al. Paclitaxel stent coating inhibits neointi-
mal hyperplasia at 4 weeks in a porcine model
of coronary restenosis. Circulation 2001;
103:2289-95.
16. Herdeg C, Oberhoff M, Baumbach A, et
al. Local paclitaxel delivery for prevention of
restenosis: biological effects and efficacy in
vivo. J Am Coll Cardiol 2000;35:1969-76.
17. Sollott SJ, Cheng L, Pauly RR, et al. Taxol
inhibits neointimal smooth muscle cell accu-
mulation after angioplasty in the rat. J Clin
Invest 1995;95:1869-76.
18. Yoon Y, Shim WH, Lee DH, et al. Useful-
ness of cilostazol versus ticlopidine in coro-
nary artery stenting. Am J Cardiol 1999;84:
1375-80.
19. Park SW, Lee CW, Kim HS, et al. Com-
parison of cilostazol versus ticlopidine ther-
apy after stent implantation. Am J Cardiol
1999;84:511-4.
20. Park SW, Lee CW, Kim HS, et al. Effects
of cilostazol on angiographic restenosis after
coronary stent placement. Am J Cardiol 2000;
86:499-503.
21. Kuntz RE, Safian RD, Carrozza JP, Fish-
man RF, Mansour M, Baim DS. The impor-
tance of acute luminal diameter in determin-
ing restenosis after coronary atherectomy or
stenting. Circulation 1992;86:1827-35.
The New England Journal of Medicine 
Downloaded from nejm.org at Yonsei Univ Coll of Medicine on July 22, 2014. For personal use only. No other uses without permission. 
 Copyright © 2003 Massachusetts Medical Society. All rights reserved. 
n engl j med 348;16 www.nejm.org april 17, 2003
paclitaxel-eluting coronary stents
1545
22. Condado JA, Waksman R, Calderas C,
Saucedo J, Lansky A. Two-year follow-up
after intracoronary gamma radiation ther-
apy. Cardiovasc Radiat Med 1999;1:30-5.
23. Teirstein PS, Massullo V, Jani S, et al.
Three-year clinical and angiographic fol-
low-up after intracoronary radiation: results
of a randomized clinical trial. Circulation
2000;101:360-5.
24. Kimura T, Abe K, Shizuta S, et al. Long-
term clinical and angiographic follow-up
after coronary stent placement in native cor-
onary arteries. Circulation 2002;105:2986-
91.
25. Lee JH, Lee CW, Park SW, et al. Long-
term follow-up after deferring angioplasty
in asymptomatic patients with moderate
noncritical in-stent restenosis. Clin Cardiol
2001;24:551-5.
26. Ormiston JA, Stewart FM, Roche AH,
Webber BJ, Whitlock RM, Webster MW. Late
regression of the dilated site after coronary
angioplasty: a 5-year quantitative angio-
graphic study. Circulation 1997;96:468-74.
27. Hermiller JB, Fry ET, Peters TF, et al. Late
coronary artery stenosis regression within
the Gianturco-Roubin intracoronary stent.
Am J Cardiol 1996;77:247-51.
28. Farb A, Heller PF, Shroff S, et al. Patho-
logical analysis of local delivery of paclitaxel
via a polymer-coated stent. Circulation 2001;
104:473-9.
Copyright © 2003 Massachusetts Medical Society.
The New England Journal of Medicine 
Downloaded from nejm.org at Yonsei Univ Coll of Medicine on July 22, 2014. For personal use only. No other uses without permission. 
 Copyright © 2003 Massachusetts Medical Society. All rights reserved. 
